ProPhase Labs, Inc. Operating Lease, Liability, Noncurrent
ProPhase Labs, Inc. (PRPH) had Operating Lease, Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-06-01
- 2025-12-31: Operating Lease, Liability, Noncurrent $0.00.
- 2025-09-30: Operating Lease, Liability, Noncurrent $0.00.
- 2025-06-30: Operating Lease, Liability, Noncurrent $0.00.
- 2025-03-31: Operating Lease, Liability, Noncurrent $3.69M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.69M 10-Q · filed 2025-05-20 |
| 2024-12-31 | $3.76M 10-K · filed 2026-06-01 |
| 2024-09-30 | $3.66M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $4.00M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $4.12M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $4.24M 10-K · filed 2025-04-01 |
| 2023-09-30 | $4.34M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.28M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $4.18M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.26M 10-K · filed 2024-03-29 |
| 2022-09-30 | $4.34M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $4.09M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $4.13M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $4.20M 10-K · filed 2023-03-29 |
| 2021-09-30 | $4.25M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $4.30M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $4.35M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $4.40M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |